Logotype for DSM Firmenich AG

DSM Firmenich (DSFIR) CMD 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for DSM Firmenich AG

CMD 2024 summary

31 Jan, 2026

Strategic transformation and portfolio focus

  • Accelerated the separation of Animal Nutrition & Health (ANH) to focus on high-growth, high-margin consumer segments in nutrition, health, and beauty, with the ANH carve-out targeted for completion by end of 2025 and estimated separation costs of ~€100mn.

  • Portfolio review advanced to 2023, deprioritizing non-core and lower-growth segments such as non-differentiated vitamins, aroma ingredients, agro ingredients, yeast extracts, and marine lipids, totaling over €600 million in sales.

  • The new structure centers on three business units: Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care, each with clear mandates for value creation, growth, and profitability.

  • Accelerated integration and transformation, including the integration of DSM and Firmenich, with a focus on maximizing synergies and consumer-driven business.

  • Strategic focus is on science-backed innovation, sustainability, and leveraging global macro trends in holistic well-being.

Financial guidance and targets

  • Mid-term targets set at 5%-7% organic sales growth, 22%-23% adjusted EBITDA margin, and cash-to-sales conversion above 10%.

  • Dividend payout ratio reaffirmed at 40%-60% of earnings, with net debt/EBITDA maintained at 1.5-2.5x to protect investment-grade rating.

  • Pathway to targets includes ~1pp annual growth from synergies and another 1pp from portfolio tuning, building on a historical 4-5% organic growth rate.

  • EBITDA margin improvement driven by vitamin transformation, synergy delivery, and business unit acceleration, up from 18% in 2023.

  • CapEx to start at 6% of sales, normalizing to 5% post-major projects, with a focus on future-proofing growth and innovation.

Innovation, science, and sustainability

  • Over €700 million invested annually in R&D, with more than 2,000 innovation staff, 16,000+ patents, and over 100 science partnerships.

  • Key innovation platforms include bioscience, microbiome, and receptor/sensor technologies, powered by digital, data science, and AI.

  • Sustainability is a core driver, with targets to reduce carbon impact by 25% by 2030, achieve net zero by 2045, and ensure 100% responsible sourcing of key ingredients by 2030; 100% renewable electricity by 2025.

  • Employee engagement remains high at 80% during transformation and integration.

  • The business model combines ingredient toolbox, creation/innovation, and customer co-creation, underpinned by science and sustainability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more